Conference Call to be Held December 19
Summary: Genmab will hold a conference call on December 19, 2007 to give an
update on the ofatumumab (HuMax-CD20) development program.
Copenhagen, Denmark; December 14, 2007 - Genmab A/S (OMX: GEN) announced today
it will give an update on the ofatumumab (HuMax-CD20(R)) development program
during a conference call on December 19, 2007 at 2:00PM GMT/3:00PM CET/9:00AM
EST. Genmab's CEO Lisa N. Drakeman, Ph.D., will be joined on the call by Dr.
Moncef Slaoui, Chairman, Research & Development at GlaxoSmithKline (GSK).
Ofatumumab is an investigational drug being developed to treat chronic
lymphocytic leukemia, follicular non-Hodgkin's lymphoma, rheumatoid arthritis
and diffuse large B-cell lymphoma under a co-development and commercialization
agreement between Genmab and GlaxoSmithKline. It is not yet approved in any
market.
Conference Call
The conference call will be held on Wednesday, December 19, 2007 at:
3:00PM CET
2:00PM GMT
9:00AM EST
The dial in numbers are as follows:
+1 800 334 0872 (in the US)
+1 913 312 1277 (outside the US)
The conference call will be held in English.
A live webcast of the call will be available at www.genmab.com. The webcast
will also be archived on Genmab's website.
About Genmab A/S
Genmab is a leading international biotechnology company focused on developing
fully human antibody therapeutics for unmet medical needs. Using unique,
cutting-edge antibody technology, Genmab's world class discovery and development
teams have created and developed an extensive pipeline of products for potential
treatment of a variety of diseases including cancer and autoimmune disorders.
As Genmab advances towards a commercial future, we remain committed to our
primary goal of improving the lives of patients who are in urgent need of new
treatment options. For more information on Genmab's products and technology,
visit www.genmab.com.
This press release contains forward looking statements. The words “believe”,
“expect”, “anticipate”, “intend” and “plan” and similar expressions identify
forward looking statements. Actual results or performance may differ materially
from any future results or performance expressed or implied by such statements.
The important factors that could cause our actual results or performance to
differ materially include, among others, risks associated with product discovery
and development, uncertainties related to the outcome and conduct of clinical
trials including unforeseen safety issues, uncertainties related to product
manufacturing, the lack of market acceptance of our products, our inability to
manage growth, the competitive environment in relation to our business area and
markets, our inability to attract and retain suitably qualified personnel, the
unenforceability or lack of protection of our patents and proprietary rights,
our relationships with affiliated entities, changes and developments in
technology which may render our products obsolete, and other factors. Genmab is
not under an obligation to up-date statements regarding the future following the
publication of this release; nor to confirm such statements in relation to
actual results, unless this is required by law.
Genmab(R); the Y-shaped Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);
HuMax-EGFr(TM); HuMax-IL8(TM); HuMax-TAC(TM); HuMax-HepC(TM); HuMax-CD38(TM);
and UniBody(R) are all trademarks of Genmab A/S.
Contact: Helle Husted, Sr. Director, Investor Relations, T: +45 33 44 77 30, M:
+45 25 27 47 13, E: hth@genmab.com
Investor News No. 17/2007
###
